Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)
NCT05275686
This study is recruiting at 4 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Eustachian Tube Dysfunction
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Cedars-Sinai Medical Center
- Last updated on ClinicalTrials.gov
- March 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Cedars-Sinai Medical Center · Los Angeles, CA
- Sacramento Ear, Nose & Throat · Sacramento, CA
Indiana · 1
- Indiana University · Indianapolis, IN
Louisiana · 1
- Ochsner Health System · New Orleans, LA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.